The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I agree with that succinct assessment, with two questions.
1. What is the likely post successful announcement share price? Will this be less than before because of the prevailing situation?
There are so many factors to consider when the announcement finally arrives. The timing will be one of the most important. I would prefer sooner rather than later, prior to the seriousness of the pandemic being overtaken by the seriousness of World events.
2. Should the potential Synairgen share price rise be less than expected, would this trigger a cut price bidding war for a takeover of the company?
This morning’s share price dip to lower than placement price levels was unexpected. Opportunistic traders will make another fortune from this while relentless “diamond hands” long term holders will have to settle for riding yet another significant dip, led by external factors this time around.
Too true BigjohnnyWin. I watched the same broadcast.
The chickens have started coming home to roost as regards the lamentable actions of some major players during the pandemic. Serious questions will now need to be asked.
Regards and good wishes.
The lack of interest is understandable. There has been nothing specific about the timeline of the forthcoming trials in which IQ-AI technology will contribute. We have received justified optimism from the company in recent months, nothing else.
The current share price action is irrelevant. The massive general market sell off yesterday was predictable. IQ-AI’d MCap was not significantly affected by this.
The Government are backing particular antiviral trials. They are inviting individuals with specific underlying conditions to participate in these extended trials. It is apparent that Synairgen continues to remain under their radar. Recently, this board discussed the underwhelming support that the Government have offered Synairgen despite the promise shown by the outcome of Phase II trials in 2020.
Another of today’s headlines was the resignation of a Conservative life peer. The reason that he gave was centred on the wasteful procurement of resources during the pandemic. His estimate, amounting to the equivalent of 1p in income tax, is a massive amount.
There are many stories like Synairgen’s, where government ministers and their affiliates have chosen to go elsewhere for wasteful solutions instead of backing British companies.
I am looking forward to the outcome of the Phase III Sprinter trials. Should they prove to be successful, the Government will have further questions to answer. I dare say that they will continue to use deflection and spin to “explain” their way out of yet another serious error in a long line of mistakes made.
Here are passages from an article on the BBC website this morning:
* Over-50s and younger adults with underlying health conditions are being urged to participate in a study of life-saving treatments for Covid-19.
* The study is open to those who test positive for Covid and had symptoms develop in the previous five days.
* Volunteers will be given pills to take at home.
The study will help decide how antiviral drugs will be used” Prof Sir Jonathan Van-Tam, the deputy chief medical officer for England, said.
* Health Secretary Sajid Javid asked everyone eligible to "step forward" and "help us to learn more about medicines which could save thousands of lives". Antivirals were "part of our approach as we learn to live with Covid, by preventing the most vulnerable from being hospitalised", he said.
* Those to be used in the Panoramic trial are:
- molnupiravir, made by Merck, Sharp and Dohme (MSD)
- paxlovid, made by Pfizer and taken alongside another drug, ritonavir
* Patients with underlying specific underlying health conditions are being invited to participate. The first on the list is:
“Chronic respiratory disease (including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma?requiring at?least daily use of preventative and/or reliever medication)?“
As thing’s stand, Mr Zamboni’s over promising, and under delivery is unworthy of praise from any investor. However the situation could quickly change provided the anticipated sequence of events, linked to the company, start to happen.
It has been particularly difficult for longer term investors. If things go according to plan, it could be well worth waiting a bit longer.
property.
I quoted the words used by contributors to the advfn board, which I occasionally visit, but do not participate in. As Docdaneeka pointed out, I should not have taken those comments on board. They could well have been put there to induce nervous under-researched investors to part with their stock?
Regards.
Woody.
Thanks for your supportive action. It is much appreciated, and I have already responded in kind to “property”’s over the top reaction to an honest rudimentary attempt to evaluate this morning’s situation.
Doc.
Yes I did. I am often told that I have been too trusting for my own good. Your comment probably reinforces that fact. As stated, this is most probably a cynical, hopefully final (although I have thought the same before) attack on the share price by short-term sellers, or big fish wanting more shares at the expense of multiple nervous small investors? The aforementioned big losers on the advfn board could well be bluffers on the take?
Regards, and best wishes to you both. It won’t be too long before the results are announced. I am confident that we will all have something to smile about whenever it happens.
property.
If my posting history were available to you, you would soon realise that it is you who is talking utter nonsense. A knee jerk reaction from an impatient, under-informed individual perhaps?
As regards those posters with “significant” losses, why not visit the advfn board and read some of today’s comments for yourself? Perhaps it hasn’t occurred to you that some recent under-researched investors may have bought a significant amount of stock in the very recent super-200p range, and panic sold under this morning’s abrupt drop? This is one of several scenarios, which a reasonably intelligent person would have been able to work out for himself/herself?
Regards.
The company itself is watertight. There have been no leaks. In my view, this is the latest “attack” by short-term sellers.
The uncertainty in world affairs is reflected in the sell off of stock. Perceptive short term sellers will be aware of the nervousness of some Synairgen investors with imminent significant news on their minds. I have read several comments from recent Synairgen investors, on other boards, claiming that they have sold their stock with significant losses this morning.
My confidence has remained intact through worse than this. A cynical attack on the share price in the absence of any updates will induce no fear in the minds of well-researched investors. It is a pre- results ploy to release shares at a late stage in the overall game. Disappointing?, yes. A cause for concern?, most definitely not!
Axe,
I have just read about yesterday’s disagreement, and recall the comment upon which it was based. The reason for this was that I had made a similar comment earlier. I subsequently thought that you had expressed the same sentiments, but much clearer, and using facts and numbers to justify your arguments. My comment was underwhelming, by comparison, to say the least.
Later, I regretted my contribution , not because of what I had said, but because a subsequent contributor asked that we limit our comments here to Synairgen-based matters, and steer away from politics. I believe that the vast majority of your comments, as well as my own, have focused on discussion relevant to our investment.
I stand by anything I may have said, which expressed the same sentiments as your comments. In my view, neither of us said anything wrong but merely expressed facts. There was nothing disparaging said about the disadvantaged in society. On a personal level, I have always tried to help those who are less fortunate than myself, as I gather is the case with most of us on this board.
Finally, I hope that you will give the matter some thought, and decide to return to the board, preferably before the results arrive. I have always valued your contributions here, and judging from this morning’s comments, I am in good company.
Regards and with my best wishes, TLW.
Fair point. That approach worked well for Steve Jobs. Who am I to challenge it ?
“You can’t connect the dots looking forward; you can only connect them looking backwards. So you have to trust that the dots will somehow connect in your future. You have to trust in something - your gut, destiny, life, karma, whatever. This approach has never let me down, and it has made all the difference in my life.”
Steve Jobs. Stanford Commencement Speech 2005.
TommyD_19
Knighthoods were handed out to the lead administrators of those trials. Mistakes were made everywhere. Governments were wrongfooted by the severity of the pandemic, and did not have the strategies or resources in place to address it.
It is probably best to look forward at this point. A successful outcome to the Synairgen Sprinter trial will result in the World being far better prepared should anything like this happen in the future.
Regards and good wishes.
Another contender ?
https://www.youtube.com/watch?v=OMOGaugKpzs
Thank you for that correction Matterhorn. I have benefited from the stream of information that you have relentlessly quoted on this board, and you are correct on this occasion.
Despite this initial “contribution”, the Government’s advisors have failed to identify the subsequent benefit that Synairgen could well have provided. I view their initial “support” as a rubber stamping exercise, nothing else. Had they been more sincere in their support, they might have followed subsequent developments more closely, and provided further assistance ?
I am essentially apolitical nowadays. Like you, I would be happy if Synairgen’s future success were steered clear of the current political minefield.
Regards and good wishes.
Rodders71.
You were evidently not on the scene the day that the Phase II home trial results were announced. They were not poor, but the trial protocols were misjudged, and there was a serious impact on a pre -announcement already declining share price. The reaction was unjustified in my view and a consequence of the actions of a number of under - researched investors who were seeking a quick profit.
The forthcoming results will undoubtedly justify my “Two out of three ain’t bad” prediction.
Regards.
I was deeply saddened to read that Meatloaf had passed on. Here is one of his hits, which could be played after Synairgen’s Sprinter results are announced.
https://m.youtube.com/watch?v=k5hWWe-ts2s
None of the Government’s advisors have offered their endorsement to Synairgen. They have not assisted with the company’s significant growth and development over the last eighteen months or so. In my opinion, some of their by now well-rewarded advisory team have probably hindered our development?
Consequently, they cannot reasonably be identified with any future success if and when it arrives. I have no doubt that a senior Government representative will be on hand should the Sprinter Phase III results justify my current substantiated optimism.
Elsol’s theory is plausible. The opportunity is there. Whether JVT, despite his significant contribution on providing essential information during the Pandemic, ought to be linked to Synairgen’s success is questionable?
I have just read today’s free summary of a business -based book on the “Blinkist” app. It is concerned with success criteria for startup businesses, but has wider applicability. It is interesting to reflect on how much these criteria have come into focus since I have been invested here. Synairgen is a strong business, which understands what it needs to do to in order to get to where it needs to go.
Here is a summary of the success criteria:
* The first is a brilliant idea. An unique solution that meets a specific customer need. It will effectively solve an important problem that customers face, and be different from anything else on the market.
* Technology and operations. These are the systems that are needed to build a product, deliver it to customers, and maintain products after sale. This will include the ways to manage inventory, and shipping, as well as sales and booking platforms for customers use.
* A profit formula. This projects the revenue the business will earn through sales, as well as the cost of earning that revenue – including the operational costs. A solid profit formula helps to confidently manage the cash flow.
*Marketing – communication with potential customers and enticing them to buy the product. Hopefully the marketing strategies will be so effective that customers will become loyal brand ambassadors, so that they can be relied upon for repeat sales.
We are not there yet, but the right framework is now well in place to ensure future success, whether Synairgen continues under its own steam or sells to a big buyer?
You may have inadvertently opened a can of worms there Doc.
https://www.youtube.com/watch?v=IxBncfGXcnE
Regards and good wishes.
Despite the arguments concerning the next steps for Synairgen, in the event of a successful Phase III Sprinter trial outcome, I am leaning towards a buyout.
It is far too early for the “living with Covid” narrative, which our Government is currently putting forward. This may well be part of the attempt, through feel-good populist headlines, to get the hapless Johnson out of his latest disaster. Synairgen has the potential to play a major part in bringing the pandemic further under control.
Synairgen is targeting the USA. This morning’s headlines in the NYT show that the situation there remains critical. A buyout from a large USA Pharmaceutical group would speed up the process to make SNG001 available as an important component of the plan to reduce hospitalisation.
This morning’s headlines:
Speaking at the online World Economic Forum, Dr. Anthony Fauci, President Biden’s top medical adviser for Covid, said it was too soon to say how the Omicron variant would change the course of the pandemic. The sheer volume of cases could have a meaningful effect on collective immunity, he said, but the evolution of the pandemic was still unclear.
“It is an open question as to whether or not Omicron is going to be the live virus vaccination that everyone is hoping for,” he said, adding: “That would only be the case if we don’t get another variant that eludes the immune response.”
Cases remain extremely high across the U.S., averaging nearly 802,000 per day, an increase of 98 percent over the past two weeks. An average of nearly 156,000 people with the virus are hospitalized nationwide, a record. Deaths now exceed 1,900 per day, up 57 percent over two weeks.
Next steps: Dr. Fauci said the world was still in the first phase of the pandemic — “where the whole world is really very negatively impacted.” The next phases are deceleration, control, elimination and eradication. In the control phase, he said, the virus will become a “nondisruptive presence” and be considered endemic.